🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12344677

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12344665

Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12344654

Mage A4 T cell receptors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12337199

Stable antibody formulation

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12338274

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12338199

Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12331109

Antigen binding molecule formats

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12331127

Therapeutic uses of anti-GITR antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12331099

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12325752

Immunoglobulin proteins that bind to NPR1 agonists

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12317874

Method of using a genetically modified mouse that expresses human albumin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12319728

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12319724

IL2 agonists and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12304969

Factor XI A2 domain-binding antibodies and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297279

Compositions and methods for treating pain in subjects with rheumatoid arthritis

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297257

Multispecific antigen-binding molecules and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297465

CBLB endonuclease variants, compositions, and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297207

Maytansinoid derivatives, conjugates thereof, and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12291559

Compositions and methods for treating cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12291571

Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 rece

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12291560

Dimerizing agent regulated immunoreceptor complexes

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281173

Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in co

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280124

Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280093

Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted